DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Keshav S, Vaňásek T, Niv Y. . Prospective Randomized Oral-Therapy Evaluation in Crohn’s Disease Trial-1 PROTECT-1 Study Group et al.
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease.
PLos One 2013;
8: e60094
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.